enos

GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.

NOS-IN-1 (2-Imino-4-methylpiperidine acetate) is a potent and orally active inhibitor of NO synthase (NOS) isoforms. NOS-IN-1 exhibits IC50s of 0.1 μM, 0.2 μM, and 1.1μM for human iNOS (hiNOS), hnNOS and heNOS, respectively.

Miconazole (R18134) is an imidazole antifungal agent used both topically and via intravenous infusion.

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

Metronidazole (Metronidazol) is a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.

L-NAME hydrochloride is an inhibitor of nitric oxide synthase (NOS) with an IC₅₀ of 70 μM, and it can be used to induce hypertension and kidney injury models.

AVE-9488 is a novel endothelial NO synthase (eNOS) enhancer that upregulates eNOS expression, induces NO production, and may ameliorate portal hypertension.

Bacoside A has a possible anticancer activity that could be inducing cell cycle arrest and apoptosis through Notch pathway in GBM in vitro. It exerts cytoprotective efficacy by attenuation of ROS generated through oxidative stress by an increase in the concentration of antioxidant enzymes and sustain membrane integrity which leads to restoring the damage caused by tBHP. Bacoside A can able to inhibit the progression of Experimental Autoimmune Encephalomyelitis (EAE) may be by the inhibition of inflammatory cytokines and chemokine evolved during active EAE. Bacoside A also has vasorelaxation.

L-NIO dihydrochloride is a potent and selective nNOS inhibitor. It reduces NO production in the CNS to protect against oxidative damage, used for neuroinflammation and pain research.

L-NMMA acetate (Tilarginine acetate) is an inhibitor of nitric oxide synthase of all NOS isoforms (i.e. NOS1, NOS2, and NOS3). The Ki values are 0.18, 0.4, and 6 µM for nNOS, eNOS, and iNOS, respectively.

TRIM (1-(2-Trifluoromethylphenyl)imidazole) is an inhibitor of nNOS.

Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.

1400W dihydrochloride (N-(3-(Aminomethyl)benzyl)acetamidine) is a highly effective and specific inhibitor of inducible NOS2 (iNOS).

Ac2-26 ammonium is an Annexin-A1 (AnxA1) N-terminal derived peptide with anti-inflammatory activity and alleviates liver ischemia-reperfusion injury in mice by regulating IL-22/IL-22R1/STAT3 signaling and eNOS pathways.

KYP-2047 is a very potent, selective Prolyl oligopeptidase (POP) inhibitor.

eNOS pT495 decoy peptide specifically inhibits T495 phosphorylation, thereby reducing eNOS uncoupling and mitochondrial redistribution. It is utilized in research on ventilator-induced lung injury [1].

GW274150 phosphate is a selective, orally active iNOS inhibitor with an IC50 of 0.2 μM in J774 cells. It mitigates experimental renal ischaemia-reperfusion injury and exhibits analgesic effects in rat models of inflammatory and neuropathic pain.

3-Deazaadenosine hydrochloride is an inhibitor of S-adenosylhomocysteine hydrolase (Ki: 3.9 µM). It has anti-inflammatory, anti-proliferative, and anti-HIV activity.

Evodenoson (ATL313) is a potent and selective adenosine A2a receptor (A2aR) agonist for the treatment of eye diseases, tumors, and immune system disorders, and may be used in studies of open-angle glaucoma and blood tumors.

1-Deazaadenosine, a potent Adenosine deaminase inhibitor (Ki: 0.66 μM), exhibits anti-cancer activities in vitro and holds potential as a chemotherapy agent for lymphoproliferative disorders.

Adenosine antagonist-1 acts as an adenosine A3 receptor (AA3R) antagonist.

N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine) is an adenosine derivative and adenosine receptor agonist with Ki values of 11.8 nM for rat A1 receptors and 30.1 nM for human A1 receptors.

N6-(4-Hydroxybenzyl)adenosine (Para-topolin riboside) is a platelet aggregation inhibitor.

Adenosine receptor antagonist 4 is an adenosine receptor antagonist.